National Health Research Institutes

Academia Sinica

Development Center for Biotechnology

Molecular Targeting Technologies. Inc.

Chiung-Tong Chen

Der-Ren Hwang

Chu-Chung Lin

Wen-Tai Li

Yu-Sheng Chao

Kak-Shan Shia

Shu-Jen Chen

Ming-Chu Hsu

Lun Kelvin Tsou

Chuan Shih

Shin-Ru Shih

Chia-Liang Tai

Jyh-Haur Chern

Chung-Chi Lee

Yen-Chun Lee

Chih-Shiang Chang

Jiing-Jyh Jan

Chih-Hao Chen

Chien-Huang Wu

Chao-Yang Huang

Hwei-Jiung Wang

Kai-Fa Huang

Szu-Liang Lai

Cheng-Chou Yu

Teng-Kuang Yeh

Wei-Ting Sun

Shu-Ping Yeh

Lun-Kelvin Tsou

Liang-Yu Hsia

Shih-Liang Hsiao

Mei-Ling Hou

Tzung-Jie Yang

Jia-ni Tian

Tzu-chin Wu

Andrew Yueh

Han-Shu Hu

Ren-Huang Wu

Pei-Shan Wu

Kuan-Hsun Huang

Tengkuang Yeh

A humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. Also, a method for treating, prophylactic treating and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, and a method or kit for detecting NTSR1 in a sample.

Humanized anti-human neurotensin receptor 1 antibodies and their uses

Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

Poly heterocyclic conjugates and their pharmaceutical uses

Benzimidazole compounds of formula (I), shown below, are disclosed. The compounds are potent human glutaminyl cyclase inhibitors. Also disclosed is a pharmaceutical composition containing one of these compounds and a pharmaceutical acceptable carrier, as well as a method of treating Alzheimer's disease or Huntington's disease by administering to a subject in need thereof an effective amount of such a compound. 

Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease

Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds.

Heterocyclic compounds and use thereof

Dipicolylamine compounds of Formula (I) set forth herein. Also disclosed are pharmaceutical compositions containing metal ions and these compounds. Further disclosed is a method for treating a condition associated with cells containing inside-out phosphatidylserine, with these compounds.

Dipicolylamine derivatives and their pharmaceutical uses

This invention relates to an oral formulation containing an effective amount of the compound of the following formula I: d-alpha-tocopheryl polyethylene glycol 1000 succinate ('TPGS'); and 2-(2-ethoxyethoxy)ethanol ('Transcutol'). Rthrough Rand n are defined herein. Also disclosed is a method of treating cancer by administering this formula to a subject orally.

Formulations of indol-3-yl-2-oxoacetamide compounds

This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: wherein R, R, R, R, and n are defined herein.

Methods of 1H-indol-3-yl-2-oxoacetamide compounds

The invention relates to novel imidazolamino compounds. Also disclosed are methods of treating cancer by using one of these compounds and pharmaceutical compositions containing one of these compounds.

Imidazolamino compounds

This invention relates to compounds of the following formula: in which R, R, A, A, X, Y, m, n, p, x and y are as defined herein, pharmaceutical compositions comprising the compounds and use of the compounds in treating enterovirus infection.

Imidazolidinone compounds

A method of treating cancer including administering to a subject in need thereof an effective amount of a compound of the formula 1: wherein R, R, R, R, and n are as defined herein.

Use of 1H-indol-3-yl-2-oxoacetamide compounds

The invention is based on the discovery that certain 3-oxoacetamideindolyl compounds have potent anticancer and anti-angiogenic activity. The 3-oxoacetamideindolyl compounds are of the following formula.In this formula, each Ris independently isoxazolyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, isoquinolyl, thionaphthenyl, or benzofuranyl, each being optionally substituted with 1-6 independent R; or when taken together with Rand the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R. Each Ris independently H, C1-C10 alkyl, or aryl, each being optionally substituted with 1-4 independent R; or when taken together with Rand the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R. Each Ris independently C3-C10 cycloalkyl, C4-C10 cycloalkenyl, isoxazolyl, furanyl, thiophenyl, thiazolyl, imidazolyl, pyridyl, or heterocyclyl, each being optionally substituted with 1-4 independent R. Each Ris independently H, NO, halo, CN, R, OR, COR, SR, NRR, C(O)R, C(O)NRR, OC(O)R, S(O)R, S(O)NRR, NRC(O)NRR, NRC(O)R, NR(COOR), NRS(O)NRR, NRS(O)R, or S(O)OR.

Indol-3-YL-2-oxoacetamide compounds and methods of use thereof

Growing community of inventors

Taipei, Taiwan

Chiung-Tong Chen